I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology 2023 ASCO Annual Meeting
Roche and Genentech at

2023 ASCO Annual Meeting

June 02 - June 06
Chicago, USA
am.asco.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 5 / Roche and Genentech
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study
In the Phase III POLARIX study, Pola-R-CHP significantly prolonged progression-free survival vs R-CHOP in patients with previously untreated DLBCL, with a similar safety profile. The prognostic value of ctDNA levels at baseline and decrease in ctDNA levels after one cycle of therapy in POLARIX have been previously validated. This analysis evaluates the relationship between undetectable ctDNA and clinical outcomes.
Haematology Oncology Diffuse large B cell lymphoma ASCO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 5 / Roche and Genentech
CAMMA 2: A Phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who are triple class refractory and have received a prior anti B-cell maturation antigen (BCMA) agent
CAMMA 2 is an open-label, multi-center phase I/II trial of cevostamab monotherapy in patients with RRMM who are triple-class refractory and have previously received a BCMA-targeted agent. Enrolment is ongoing.
Oncology Multiple Myeloma ASCO-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 5 / Roche and Genentech
Subgroup analysis of elderly patients with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study
In the Phase 3 POLARIX study, Pola-R-CHP significantly prolonged progression-free survival vs R-CHOP, with a similar safety profile, in patients aged 18–80 years with previously untreated DLBCL. Combination regimens may be associated with higher rates of toxicity in elderly patients. This analysis reports the efficacy and safety of Pola-R-CHP vs R CHOP in patients aged ≥70 years enrolled in POLARIX.
Haematology Oncology Diffuse large B cell lymphoma ASCO-2023
04:45 PM
Duration 6mins E450
Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study
Petra Budde, Delvys Rodriguez Abreu, Hans-Dieter Zucht, Divya Shrivastava, Annika L. Kilian, Elen Hoglander, Stefaniya Shoshkova, Marija Markovic, Monika Kaul, Jose Vicente Cardona, G Scott Chandler, Rajat Mohindra
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:54 PM
Duration 12mins Virtual
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
Richard S. Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng, Adam Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Ed Gane
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 AM
Duration 12mins Hall D1
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor treatment in metastatic renal cell carcinoma: Phase III CONTACT-03 study
Choueiri T, Piotr T, Albiges L, Suárez C, Voss M, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Chan K, Powles T, Gupta S, Kalaitzidou M, Scheffold C, Pal K S, Mochalova A
Oncology | Genitourinary cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 12mins Arie Crown Theater
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Masatoshi Kudo, Minshan Chen, Pierce Chow, Ahmed Kaseb, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
Oncology | Gastrointestinal Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:42 PM
Duration 12mins Hall D1
Overall survival by response to first-line induction treatment with atezolizumab + platinum/gemcitabine vs placebo + plt/gem in patients with metastatic urothelial carcinoma: updated data from the IMvigor130 OS final analysis
Grande E, Bamias A, Galsky MD, Kikuchi E, Davis ID, Arranz JA, Rezazadeh Kalebasty A, Garcia del Muro X, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Puente J, Li J-R, Lee C, Bernhard S, Nicholas A, Telliez J, De Santis M
Oncology | Genitourinary cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Presented at this congress:

 

Poster:

Global prevalence of CLDN18.2-positivity in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

Authors: Shitara K, Xu RH, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ajani JA, Shah MA

This file is not available.

Presented at this congress:

 

Poster:

LungFlag, a Machine-Learning (ML) Personalized Tool for Assessing Lung Cancer Risk in a Community Setting, Demonstrates Comparable Performance in Flagging Non-Small Cell Lung Cancer (NSCLC) Regardless of Sex or Race

Authors: Choman EN, Morgenstern D

This file is not available.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.